Alzheimer's disease: new pharmacological perspectives.
Laboratorios Almirall, Research Centre, Barcelona, Spain.
J M
JM
Palacios
D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D010091:Oximes / Q000627:therapeutic use; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D000068836:Rivastigmine; D013619:Tacrine / Q000627:therapeutic use; D013830:Thiadiazoles / Q000627:therapeutic use
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D004095:Dihydropyridines; D007189:Indans; D018721:Muscarinic Agonists; D010091:Oximes; D048448:Phenylcarbamates; D010880:Piperidines; D011725:Pyridines; D013830:Thiadiazoles; D013619:Tacrine; D000077265:Donepezil; C075257:xanomeline; D000068836:Rivastigmine; C084978:milameline